Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06997809
Recruiting Not applicable

ENDometriosis: Evaluation of Detection and Need for ALGOlogic Care Before Surgery

NCT06997809 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Limoges
Phase
Not applicable
Started
2026-08-05
Last updated
2026-09-04

Condition(s) studied

Endometriosis, Pain

Investigational drug(s) / intervention(s)

pathway care

pathway care: Group for whom the test results will be used to determine the management strategy. If one of the tests performed before randomization is positive an algological consultation before surgery will be performed with an adapted treatment. Then surgical treatment as planned. If all tests are negative, surgical treatment is performed. The dedicated algology consultation must be done with an experienced practitioner different from the one who will perform the surgery. A rapid algological treatment circuit must be put in place to maintain the surgery date set. Group without using the results of test for associated pain components. Standard surgical treatment as planned through dedicated staff on endometriosis treatment.

Study summary

Endometriosis surgery is required when medical treatment fails to release women from pain. However, complete surgery does not work every time to improve patients' symptoms. Algological care is one of the options to treat the pain before surgery and their related complications (neuropathy, sensitization, and catastrophism) that could be associated to nociceptive pain.

But not all patients could benefit from this pathway and no screening strategy does exist to detect these complications that could be treated prior to endometriosis surgery

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion criteria: * Maternal age from 18 up to 50 years old (50 non included). * Women affiliated to social coverage insurance * Women who understand French * Women who signed the written consent * Women with impaired quality of life (pain) linked to endometriosis * Women with formal radiological signs of endometriosis (MRI lesions more than 5 mm or endometrioma more than 20 mm on radiological examinations). * Surgical indication for resection of lesions by laparoscopy or robotic surgery for management of pain or impairment of quality of life * Patients requiring complete conservative or radical resections of all lesions * Indication of surgery validated within dedicated meeting for endometriosis. * Purpose of pain associated or not with infertility * Date of surgery fixed with sufficient time for algological treatment. Maximum delay of 4 months between randomization and surgery Exclusion criteria: * Women undergoing surgery for the purpose of infertility * Patient with previous surgery for removal of deep lesions of endometriosis or endometriotic cysts (history of exploratory laparoscopy accepted) * Patient with suspicious lesions on MRI or specialized ultrasound. * A patient who needs to be treated for another uterine pathology at the same time. * Pregnant women * Patient with a desire for pregnancy immediately and/or within one year after surgery * Women who refuse clinical examination (some algological tests couldn't be performed without clinical examination) * Patient who has already received algological treatment or who should receive it before surgery * Patient with previous other psychiatric disorders (depressive symptoms treated) * Women without rights

Primary outcome measure(s)

  • Evaluation of quality of life — 1 year after surgery
    Quality of life is assessed by the EHP5 score translated in French and validated in endometriosis. The primary endpoint is the comparison of EHP5 scores between the 2 groups (intervention vs. standard treatment) at 1 year after surgery for complete removal of deep endometriosis

Trial sites (9)

FacilityCityRegionStatus
Bordeaux University Hospital Bordeaux France Not Yet Recruiting
IFEMENDO Bordeaux France Not Yet Recruiting
Versailles Hospital Le Chesnay France Not Yet Recruiting
Saint-Vincent-de-Paul Hospital Lille France Not Yet Recruiting
Limoges University hospital Limoges France Recruiting
Poissy-St-Germain Intercommunal hospital center Poissy France Not Yet Recruiting
Poitiers University Hospital Poitiers France Not Yet Recruiting
Mutual Clinic La Sagesse Rennes France Not Yet Recruiting
South Hospital Rennes University Hospital Rennes France Not Yet Recruiting

More University Hospital, Limoges trials in France

Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves Recruiting
Childhood Traumas in Obese Women: Association With Deregulation of the Glucocorticoid Axis and Inflammatory State. Recruiting
MICropsampling for CAffeine in PREMature Newborns Starting soon
Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France Starting soon
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06997809 on ClinicalTrials.gov ↗ ← All trials in France